The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Opioid antagonists for alcohol dependence
Abstract
BACKGROUND: Opioid antagonists can decrease alcohol consumption in animals. Their harms and benefits have been examined in many clinical trials. OBJECTIVES: To determine the effectiveness of opioid antagonists in attenuating or preventing the recommencement of alcohol consumption in patients with alcohol dependence in comparison to placebo, other medications and psychosocial treatments. In addition, discontinuation rate, death, patient satisfaction, functioning, health-related quality of life and economic outcomes were also evaluated. SEARCH STRATEGY: The specialised register of the Cochrane Group on Drugs and Alcohol was searched until September 2003. The search was integrated with previous searches of Cochrane Controlled Trials Register (Cochrane Library 2001, issue 4), MEDLINE (1966 - October 2001), EMBASE (1980 - December 2001) and CINHAL (1982 - December 2001). Du Pont Pharmaceutical and Ivax Corporation were contacted for information regarding unpublished trials. The reference lists of the obtained papers were also examined. SELECTION CRITERIA: All relevant randomised controlled trials (RCTs) were included. Participants were people with alcohol dependence. Naltrexone (NTX), nalmefene (NMF) and other opioid antagonists with/without other biological or psychosocial treatments were examined. Two primary outcomes were number of participants with relapses (including those who return to heavy drinking) and number of participants who return to drinking. Other outcomes of interest were time to first drink, percentage or number of drinking days, number of standard drinks, craving, percentage or number of days or episodes of heavy drinking, amount of alcohol consumed, discontinuation rate, patient satisfaction, impaired function, health-related quality of life, economic and death. DATA COLLECTION AND ANALYSIS: Two reviewers evaluated and extracted the data independently. The dichotomous data were extracted on an intention-to-treat basis. The Relative Risk with the 95% confidence interval was used to assess the dichotomous data. A weighted (or standardised) mean difference (WMD or SMD) with 95% confidence interval was used to assess the continuous data. MAIN RESULTS: The review included 29 RCTs presented in 36 articles. Except two RCTs of nalmefene, all others investigated NTX. In comparison to placebo, a short-term treatment of NTX significantly decreased the relapse [RR (95% CI) = 0.64 (0.51 to 0.82)] and was likely to decrease the return to drinking [RR (95% CI) = 0.87 (0.76 to 1.00). In the respect of acceptability, NTX treatment significantly diminished treatment withdrawal [RR (95% CI) = 0.82 (0.70 to 0.97). While a medium-term treatment of NTX gave no benefit in the respect of relapse prevention, it was found to be beneficial on two of four secondary outcomes by increasing time to first drink and diminishing craving. A medium-term treatment of NTX was superior to acamprosate in reducing relapses, standard drinks and craving. NTX plus an intensive psychosocial treatment (PST) was not superior to NTX plus a simple PST on any primary and secondary short-term outcomes. For a medium-term treatment, NTX plus an intensive PST was superior to NTX plus a simple PST in increasing time to first drink and decreasing craving. AUTHORS' CONCLUSIONS: The review findings support that short-term treatment of NTX decreases the chance of alcohol relapses for 36% (number-needed-to-treat or NNT = 7) and likely to reduce the chance of returning to drinking for 13% (NNT = 12). In comparison to placebo group, NTX treatment can lower the risk of treatment withdrawal in alcohol-dependent patients for 28% (NNT = 13). Some major limitations of the available evidence include short study duration in many trials, small sample sizes in most trials and lack of data on psychosocial benefits. In conclusion, NTX should be accepted as a short-term treatment for alcoholism. Strategies to improve adherence to NTX treatment, eg, PSTs and management of adverse effects, should be concomitantly given. We have not yet known so far how long alcohol-dependent patients who respond to NTX treatment should continue their treatment. Due to too little evidence, NMF should have no role for the treatment of alcohol dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Regier, D. A. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820140007001 · Cited by 1,999
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Endogenous opioid systems and alcohol addiction
Herz, A. (1997) · Psychopharmacology · doi:10.1007/s002130050169 · Cited by 759
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
O'Malley, S., Krishnan-Sarin, S., Farren, C., Sinha, R., & Kreek, M. (2002) · Psychopharmacology · doi:10.1007/s002130100919 · Cited by 492
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444
Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1758 · Cited by 425
Naltrexone and Alcohol Dependence: Role of Subject Compliance
Volpicelli, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200071010 · Cited by 411
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400
Rating the quality of evidence for clinical practice guidelines
Hadorn, D. C., Baker, D., Hodges, J. S., & Hicks, N. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00019-4 · Cited by 332
Chick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310
Effect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes
Spanagel, R., & Zieglgänsberger, W. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)89800-8 · Cited by 291
Six-Month Follow-up of Naltrexone and Psychotherapy for Alcohol Dependence
O'Malley, S. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830030039007 · Cited by 282
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C., & Cutler, R. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.719 · Cited by 271
Should Unpublished Data Be Included in Meta-analyses?: Current Convictions and Controversies
Cook, D. J. (1993) · JAMA · doi:10.1001/jama.1993.03500210049030 · Cited by 259
Mason, B. J., Ritvo, E. C., Morgan, R. O., Salvato, F. R., Goldberg, G., Welch, B., & Mantero‐Atienza, E. (1994) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1994.tb00098.x · Cited by 248
King, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227
Heinälä, P., Alho, H., Kiianmaa, K., Lönnqvist, J., Kuoppasalmi, K., & Sinclair, J. D. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00006 · Cited by 226
Croop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211
Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial
Kranzler, H. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00135-9 · Cited by 209
Analysis of Randomized Controlled Trials
Peduzzi, P. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/24.1.26 · Cited by 201
Naltrexone for alcohol dependence: a randomized controlled trial
Morris, P. L. P., Hopwood, M., Whelan, G., Gardiner, J., & Drummond, E. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961115654.x · Cited by 200
Lithium Treatment of Depressed and Nondepressed Alcoholics
Dorus, W. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430120100029 · Cited by 174
Balldin, J., Berglund, M., Borg, S., Månsson, M., Bendtsen, P., Franck, J., Gustafsson, L., Halldin, J., Nilsson, L. ‐. H., Stolt, G., et al. (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000075548.83053.a9 · Cited by 173
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings
Johnson, B. A., & Ait-Daoud, N. (2000) · Psychopharmacology · doi:10.1007/s002130000371 · Cited by 172
Effects of Naltrexone on Alcohol Self-Administration in Heavy Drinkers
Davidson, D., Palfai, T., Bird, C., & Swift, R. (1999) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199902000-00001 · Cited by 165
Jaffe, A. J., Rounsaville, B. J., Chang, G., Schottenfeld, R. S., Meyer, R. E., & O'Malley, S. S. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.5.1044 · Cited by 149
Naltrexone as an Adjunctive Treatment for Older Patients With Alcohol Dependence
Oslin, D. W., Liberto, J. G., O'Brien, J. T., Krois, S., & Norbeck, J. (1997) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199700540-00007 · Cited by 143
O’Malley, S. S., Rounsaville, B. J., Farren, C. K., Namkoong, K., Wu, R., Robinson, J., & O’Connor, P. G. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1695 · Cited by 142
Guardia, J., Caso, C., Árias, F., Gual, A., Sanahuja, J., Ramírez, M., Mengual, I., Gonzalvo, B., Segura, L., Trujols, J., et al. (2002) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02682.x · Cited by 135
Gastpar, M., Bonnet, U., Böning, J., Mann, K. F., Schmidt, L., Soyka, M., Wetterling, T., Kielstein, V., Labriola, D., & Croop, R. S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00009 · Cited by 131
PROPHYLACTIC TREATMENT OF ALCOHOLISM BY LITHIUM CARBONATE A Controlled Study
Merry, J., Reynolds, C. W., Bailey, J., & Coppen, A. J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90784-4 · Cited by 129
Latt, N. C., Jurd, S. M., Houseman, J., & Wutzke, S. E. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04550.x · Cited by 128
Pettinati, H. M., Volpicelli, J. R., Pierce, J. D., & O’Brien, C. P. (2000) · Journal of Addictive Diseases · doi:10.1300/j069v19n01_06 · Cited by 122
NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT
Rubio, G. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.5.419 · Cited by 116
Naltrexone Increases the Latency to Drink Alcohol in Social Drinkers
Davidson, D., Swift, R. M., & Fitz, E. (1996) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01679.x · Cited by 111
Naltrexone treatment of comorbid alcohol and cocaine use disorders
Hersh, D., Kirk, J. R. V., & Kranzler, H. R. (1998) · Psychopharmacology · doi:10.1007/s002130050688 · Cited by 93
Anton, R. F., Moak, D. H., Latham, P. K., Waid, L. R., Malcolm, R. J., Dias, J. K., & Roberts, J. S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00013 · Cited by 90
Johnson, B. A., Ait‐Daoud, N., & Prihoda, T. J. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb02048.x · Cited by 89
Carroll, K. M., Ziedonis, D. M., O’Malley, S. S., McCance‐Katz, E. F., Gordon, L. T., & Rounsaville, B. J. (1993) · American Journal on Addictions · doi:10.3109/10550499309115944 · Cited by 83
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption
Stromberg, M. F., Mackler, S. A., Volpicelli, J. R., & O’Brien, C. P. (2001) · Alcohol · doi:10.1016/s0741-8329(00)00137-3 · Cited by 81
The Effects of Naltrexone on Alcohol and Cocaine Use in Dually Addicted Patients
Oslin, D. W., Pettinati, H. M., Volpicelli, J. R., Wolf, A. L., Kampman, K. M., & O’Brien, C. P. (1999) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(98)00039-7 · Cited by 69
Predictors of Compliance with Naltrexone Among Alcoholics
Rohsenow, D. J., Colby, S. M., Monti, P. M., Swift, R. M., Martin, R. A., Mueller, T. I., Gordon, A. A., & Eaton, C. A. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb04573.x · Cited by 68
Alcohol drinking in rats during and following morphine injections
Volpicelli, J. R., Ulm, R. R., & Hopson, N. (1991) · Alcohol · doi:10.1016/0741-8329(91)90401-h · Cited by 60
Serum 6-Beta-Naltrexol Levels Are Related to Alcohol Responses in Heavy Drinkers
McCaul, M. E., Wand, G. S., Rohde, C. A., & Lee, S. M. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb02107.x · Cited by 59
O’Malley, S. S., Krishnan‐Sarin, S., Farren, C. K., & O’Connor, P. G. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00012 · Cited by 58
Effects of naltrexone on cue-elicited craving for alcohol and cocaine
Modesto‐Lowe, V., Burleson, J. A., Hersh, D., Bauer, L. O., & Kranzler, H. R. (1997) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(97)00134-8 · Cited by 47
Naltrexone and Brief Counseling to Reduce Heavy Drinking: Results of a Small Clinical Trial
Bohn, M. J., Kranzler, H. R., Beazoglou, D., & Staehler, B. A. (1994) · American Journal on Addictions · doi:10.1111/j.1521-0391.1994.tb00375.x · Cited by 44
Modulation of ethanol-intake by morphine: Evidence for a central site of action
Wild, K. D., & Reid, L. D. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90221-c · Cited by 34
Naltrexone improves outcome of a controlled drinking program
Rubio, G., Manzanares, J., Lopez-Munoz, F. J., Álamo, C., Ponce, G., Jiménez‐Arriero, M. Á., & Palomo, T. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00296-9 · Cited by 33
Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore
Lee, A. M., Tan, S., Lim, D., Winslow, R. M., Wong, K. E., Allen, J., Hall, W., & Parker, G. B. (2001) · Drug and Alcohol Review · doi:10.1080/09595230124192 · Cited by 28
Tolerability of Naltrexone in Treating Older, Alcohol-Dependent Patients
Oslin, D. W., Liberto, J. G., O’Brien, J. F., & Krois, S. (1997) · American Journal on Addictions · doi:10.1111/j.1521-0391.1997.tb00406.x · Cited by 22
Using Naltrexone in Inpatient Alcoholism Treatment
Knox, P. C., & Donovan, D. M. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471767 · Cited by 20
Feeney, G. F. X., Feeney, G. F. X., Young, R. M., Connor, J. P., Tucker, J., & McPherson, A. (2001) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2001.00935.x · Cited by 19
The use of naltrexone to treat ambulatory patients with alcohol dependence.
Nj, G., Díaz Ramírez, D., de Guzman, F. S., et al. (1998) · PubMed · Cited by 14
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol
Anderson, P., Chisholm, D., & Fuhr, D. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60744-3 · Cited by 1,102
O'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
Metadata
- Authors
- Srisurapanont, M., & Jarusuraisin, N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2005-01-24
- Issue
- 1
- Pages
- CD001867-CD001867
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4205732724
- Cited by
- 265
- References
- 62
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.